Meeting
2022 ASCO Genitourinary Cancers Symposium
Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Authors
Vishal Navani
Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
Vishal Navani , Matthew Scott Ernst , Connor Wells , Takeshi Yuasa , Kosuke Takemura , Frede Donskov , Naveen S. Basappa , Andrew Lachlan Schmidt , Sumanta K. Pal , Luis A Meza , Lori Wood , D. Scott Ernst , Bernadett Szabados , Rana R. McKay , Andrew James Weickhardt , Cristina Suárez , Anil Kapoor , Jae-Lyun Lee , Toni K. Choueiri , Daniel Yick Chin Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 310)
DOI
10.1200/JCO.2022.40.6_suppl.310
Abstract #
310
Poster Bd #
D12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Micah Ostrowski
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan